Meta-analysis in transfusion medicine

Transfusion

Volumn 37, Issue 3, 1997, Pages 329-345

  Vamvakas, E C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD COMPONENT THERAPY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; HEALTH CARE POLICY; MEDICAL RESEARCH; META ANALYSIS; MULTIPLE SCLEROSIS; NEWBORN SEPSIS; POSTOPERATIVE INFECTION; PRACTICE GUIDELINE; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; RECURRENT ABORTION; REVIEW;

EID: 0030945195     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1997.37397240218.x     Document Type: Review

References (184)

1. Jenicek M. Meta-analysis in medicine. Where we are and where we want to go. J Clin Epidemiol 1989;42:35-44.
2. Goodman SN. Have you ever meta-analysis you didn't like? (editorial). Ann Intern Med 1991;114:244-6.
3. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Ann Intern Med 1987;107:224-33.
4. Glass GV. Primary, secondary, and meta-analysis of research. Educ Res 1976;5:3-8.
5. Fleiss JL, Tytum A, Ury HK. A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 1980;36:343-6.
6. Freiman JA, Chalmers TC, Smith H Jr, Kuebler RR. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials. N Engl J Med 1978;299:690-4.
7. Boden WE. Meta-analysis in clinical trials reporting: has a tool become a weapon? (editorial). Am J Cardiol 1992;69:681-6.
8. Passamani E. Clinical trials - are they ethical? N Engl J Med 1991;324:1589-92.
9. Hellman S, Hellman DS. Of mice but not men. Problems of the randomized clinical trial. N Engl J Med 1991;324:1585-9.
10. O'Rourke K, Detsky AS. Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts. J Clin Epidemiol 1989;42:1021-4.
11. Fleiss JL, Gross AJ. Meta-analysis in epidemiology, with special reference to studies of the association between exposure to environmental tobacco smoke and lung cancer: a critique. J Clin Epidemiol 1991;44:127-39.
12. Chalmers TC, Lau J. Meta-analytic stimulus for changes in clinical trials. Stat Methods Med Res 1993;2:161-72.
13. Moher D, Olkin I. Meta-analysis of randomized controlled trials. A concern for standards. JAMA 1995;274:1962-4.
14. Chalmers TC, Matta RJ, Smith H Jr, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med 1977;297:1091-6.
15. Stampfer MJ, Goldhaber SZ, Yusuf S, et al. Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. N Engl J Med 1982;307:1180-2.
16. Himel NH, Liberati A, Gelber RD, Chalmers TC. Adjuvant chemotherapy for breast cancer. A pooled estimate based on published randomized controlled trials. JAMA 1986;256:1148-59.
17. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988;319:1681-92.
18. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Center Trialists' Collaborative Group. Lancet 1992;339:1-15.
19. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 1984;311:1528-33.
20. Andersen JW, Harrington D. Meta-analyses need new publication standards (editorial). J Clin Oncol 1992;10:878-80.
21. Sacks HS, Berrier J, Reitman D, et al. Meta-analyses of randomized controlled trials. N Engl J Med 1987;316:450-5.
22. Mann C. Meta-analysis in the breech (news). Science 1990;249:476-80.
23. Schiffer CA, Dutcher JP, Aisner J, et al. A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia. Blood 1983;62:815-20.
24. Andreu G, Dewailly J, Leberre C, et al. Prevention of HLA immunization with leukocyte-poor packed red cells and platelet concentrates obtained by filtration. Blood 1988;72:964-9.
25. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. Blood 1988;71:1402-7.
26. Oksanen K, Kekomäki R, Ruutu T, et al. Prevention of alloimmunization in patients with acute leukemia by use of white cell-reduced blood components - a randomized trial. Transfusion 1991;31:588-94.
27. Van Marwijk Kooy M, van Prooijen HC, Moes M, et al. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. Blood 1991;77:201-5.
28. Williamson LM, Wimperis JZ, Williamson P, et al. Bedside filtration of blood products in the prevention of HLA alloimmunization - a prospective randomized study. Blood 1994;83:3028-35.
29. Elghouzzi MH, Vedrenne JB, Jullien AM, et al. [Technical, immunological, and clinical study of the performance of blood filtration using Erypur filters] (Engl abstract). Rev Fr Transfus Immunohematol 1981;24:579-95.
30. Rebulla P, Andreis C, Barbui T, et al. A clinical trial on the efficacy of leukocyte-depleted blood components in preventing refractoriness to random platelet support. In: Barbui T, Falange A, Minetti B, et al., eds. Infection and hemorrhage in acute leukemia. Paris: Libbey Eurotext, 1989:89-100.
31. Handa M, Ikeda Y, Kurata Y, et al. [Efficacy of leukocyte-depleted platelet concentrates for prevention of HLA-alloimmunization in patients with frequent platelet transfusion: a prospective multi-institutional study using a polyester platelet filter] (Engl abstract), Rinsho Ketsueki 1992;33:451-60.
32. Heddle NM. The efficacy of leukodepletion to improve platelet transfusion response: a critical appraisal of clinical studies. Transfus Med Rev 1994;8:15-28.
33. Andreu G, Dewailly J. Prevention of HLA alloimmunization by using leukocyte-depleted components. Curr Stud Hematol Blood Transfus 1994;60:29-40.
34. Woolley AL, Hogikyan ND, Gates GA, et al. Effect of blood transfusion on recurrence of head and neck carcinoma. Retrospective review and meta-analysis. Ann Otol Rhinol Laryngol 1992;101:724-30.
35. Chung M, Steinmetz OK, Gordon PH. Perioperative blood transfusion and outcome after resection for colorectal carcinoma. Br J Surg 1993;80:427-32.
36. Amato A, Pescatori M. Perioperative blood transfusion and outcome after resection for colorectal carcinoma (letter). Br J Surg 1994;81:313-4.
37. Vamvakas EC. Perioperative blood transfusion and cancer recurrence: meta-analysis for explanation. Transfusion 1995;35:760-8.
38. Busch OR, Hop WC, Hoynck van Papendrecht MA, et al. Blood transfusions and prognosis in colorectal cancer. N Engl J Med 1993;328:1372-6.
39. Heiss MM, Mempel W, Delanoff C, et al. Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery. J Clin Oncol 1994;12:1859-67.
40. Houbiers JG, Brand A, van de Watering LM, et al. Randomised controlled trial comparing transfusion of leucocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344:573-8.
41. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79:513-6.
42. Heiss MM, Mempel W, Jauch KW, et al. Beneficial effect of autologous blood transfusion on infectious complications after colorectal cancer surgery. Lancet 1993;342:1328-33.
43. Busch OR, Hop WC, Marquer RL, Jeekel J. Autologous blood and infections after colorectal surgery (letter). Lancet 1994;343:668-9.
44. Vamvakas EC. Transfusion-associated cancer recurrence and postoperative infection: meta-analysis of randomized, controlled clinical trials. Transfusion 1996;36:175-86.
45. Mowbray JF, Gibbings C, Liddell H, et al. Controlled trial of treatment of recurrent spontaneous abortion by immunisation with paternal cells. Lancet 1985;1:941-3.
46. Ho HN, Gill TJ 3d, Hsieh HJ, et al. Immunotherapy for recurrent spontaneous abortions in a Chinese population. Am J Reprod Immunol 1991;25:10-5.
47. Cauchi MN, Lim D, Young DE, et al. Treatment of recurrent aborters by immunization with paternal cells - controlled trial. Am J Reprod Immunol 1991;25:16-7.
48. Gatenby PA, Cameron K, Simes RJ, et al. Treatment of recurrent spontaneous abortion by immunization with paternal lymphocytes: results of a controlled trial. Am J Reprod Immunol 1993;29:88-94.
49. Worldwide collaborative observational study and meta-analysis on allogeneic leukocyte immunotherapy for recurrent spontaneous abortion. Recurrent Miscarriage Immunotherapy Trialists Group. Am J Reprod Immunol 1994;32:55-72.
50. Cowchock S. What's a mother to do? Analysis of trials evaluating new treatments for unexplained recurrent miscarriages and other complaints (editorial). Am J Reprod Immunol 1991;26:156-9.
51. Fraser EJ, Grimes DA, Schulz KF. Immunization as therapy for recurrent spontaneous abortion: a review and meta-analysis. Obstet Gynecol 1993;82:854-9.
52. Jeng GT, Scott JR, Burmeister LF. A comparison of meta-analytic results using literature vs individual patient data. Paternal cell immunization for recurrent miscarriage. JAMA 1995;274:830-6.
53. Laurenti F, Ferro R, Isacchi G, et al. Polymorphonuclear leukocyte transfusion for the treatment of sepsis in the newborn infant. J Pediatr 1981;98:118-23.
54. Christensen RD, Rothstein G, Anstall HB, Bybee B. Granulocyte transfusions in neonates with bacterial infection, neutropenia, and depletion of mature marrow neutrophils. Pediatrics 1982;70:1-6.
55. Cairo MS, Worcester C, Rucker R, et al. Role of circulating complement and polymorphonuclear leukocyte transfusion in treatment and outcome in critically ill neonates with sepsis. J Pediatr 1987;110:935-41.
56. Wheeler JG, Chauvenet AR, Johnson CA, et al. Buffy coat transfusions in neonates with sepsis and neutrophil storage pool depletion. Pediatrics 1987;79:422-5.
57. Baley JE, Stork EK, Warkentin PI, Shurin SB. Buffy coat transfusions in neutropenic neonates with presumed sepsis: a prospective, randomized trial. Pediatrics 1987;80:712-20.
58. Vamvakas EC, Pineda AA. Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apheresis 1996;11:1-9.
59. Vamvakas EC, Pineda AA, Weinshenker BG. Meta-analysis of clinical studies of the efficacy of plasma exchange in the treatment of chronic progressive multiple sclerosis. J Clin Apheresis 1995;10:163-70.
60. Phillips K. The use of meta-analysis in technology assessment: a meta-analysis of the enzyme immunosorbent assay human immunodeficiency virus antibody test. J Clin Epidemiol 1991;44:925-31.
61. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995;89:67-71.
62. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med 1992;117:739-48.
63. Pagliaro L, Craxi A, Cammaa C, et al. Interferon-alpha for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-8.
64. Begg CB, Pilote L, McGlave PB. Bone marrow transplantation versus chemotherapy in acute non-lymphocytic leukemia: a meta-analytic review. Eur J Cancer Clin Oncol 1989;25:1519-23.
65. Proceedings of "Methodologic issues in overviews of randomized clinical trials." The National Heart, Lung and Blood Institute and the National Cancer Institute, Bethesda, Maryland, 15-16 May, 1986. Stat Med 1987;6:217-409.
66. Hedges LV, Olkin I. Statistical methods for meta-analysis. Orlando, FL: Academic Press, 1985.
67. Glass GV, McGraw B, Smith ML. Meta-analysis in social research. Beverly Hills, CA: Sage Publications, 1981.
68. Cooper H, Hedges LV, eds. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
69. Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge, MA: Harvard University Press, 1984.
70. Jenicek M. Meta-analyse en medecine: Evaluation et synthese de l'information clinique et epidemiologique. St Hyacinthe, Quebec, et Paris: Edisem et Maloine, 1987.
71. Halvorsen KT. Combining results from independent investigations: meta-analysis in medical research. In: Bailar JC III, Mosteller F, eds. Medical uses of statistics. Waltham, MA: NEJM Books, 1986:392-416.
72. Fletcher RH, Fletcher SW, Wagner EH. Clinical epidemiology -the essentials. 2nd ed. Baltimore: Williams & Wilkins, 1988:226-40.
73. Felson DT. Bias in meta-analytic research. J Clin Epidemiol 1992;45:885-92.
74. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
75. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
76. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986;7:177-88.
77. Wolf FM. Meta-analysis: quantitative methods for research synthesis. Newbury Park, CA: Sage Publications, 1986.
78. Prentice RL, Thomas DB. On the epidemiology of oral contraceptives and disease. Adv Cancer Res 1987;49:285-401.
79. Hennekens CH, Buring JE. Epidemiology in medicine. Boston: Little, Brown, 1987:30-53.
80. Schlesselman JJ. Case-control studies: design, conduct, analysis. New York: Oxford University Press, 1982:227-90.
81. Datta M. You cannot exclude the explanation you have not considered. Lancet 1993;342:345-7.
82. Chalmers TC, Levin H, Sacks HS, et al. Meta-analysis of clinical trials as a scientific discipline. I: Control of bias and comparison with large co-operative trials. Stat Med 1987;6:315-28.
83. Peto R. Why do we need systematic overviews of randomized trials? Stat Med 1987;6:233-44.
84. Yusuf S. Obtaining medically meaningful answers from an overview of randomized clinical trials. Stat Med 1987;6:281-94.
85. Spitzer WO. Meta-analysis: unanswered questions about aggregating data (editorial). J Clin Epidemiol 1991;44:103-7.
86. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 1976;34:585-612.
87. May GS, DeMets DL, Friedman LM, et al. The randomized clinical trial: bias in analysis. Circulation 1981;64:669-73.
88. Friedman LM, Furberg CD, DeMets DL. Fundamentals of clinical trials. Littleton, MA: PSG, 1985.
89. Collins R, Gray R, Godwin J, Peto R. Avoidance of large biases and large random errors in the assessment of moderate treatment effects: the need for systematic overviews. Stat Med 1987;6:245-54.
90. Halperin M, DeMets DL, Ware JH. Early methodological developments for clinical trials at the National Heart, Lung and Blood Institute. Stat Med 1990;9:881-92; discussion, 903-6.
91. Sackett DL, Gent M. Controversy in counting and attributing events in clinical trials. N Engl J Med 1979;301:1410-2.
92. Chalmers TC, Smith H Jr, Blackburn B, et al. A method for assessing the quality of a randomized control trial. Controlled Clin Trials 1981;2:31-49.
93. Howard VJ, Grizzle J, Diener HC, et al. Comparison of multicenter study designs for investigation of carotid endarterectomy efficacy. Stroke 1992;23:583-93.
94. Fleiss JL. Multicenter clinical trials: Bradford Hill's contributions and some subsequent developments. Stat Med 1982;1:353-9.
95. McCullough J. Granulocytetransfusion. In: Petz LD, Swisher SN, Kleinman S, et al., eds. Clinical practice of transfusion medicine. 3rd ed. New York: Churchill Livingstone, 1996:413-32.
96. Strauss RG. Granulocyte transfusions. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of transfusion medicine. 2nd ed. Baltimore: William & Wilkins, 1996:321-43.
97. Berlin JA, Laird NM, Sacks HS, Chalmers TC. A comparison of statistical methods for combining event rates from clinical trials. Stat Med 1989;8:141-51.
98. Thompson SG, Pocock SJ. Can meta-analysis be trusted? Lancet 1991;338:1127-30.
99. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987;6:341-50.
100. Meier P. Commentary on "Why do we need systematic overviews of randomized trials?" Stat Med 1987;6:329-31.
101. Bailey KR. Inter-study differences: how should they influence the interpretation and analysis of results? Stat Med 1987;6:351-60.
102. Tollner F, Pholandt F, Heinze F, Henrichs I. Treatment of septicemia in the newborn infant: choice of initial antimicrobial drugs and the role of exchange transfusion. Acta Pediatr Scand 1977;66:605-10.
103. Pearse RG, Sauer PJ. Exchange transfusion in treatment of severe infection in newborn and of sclerema neonatorum. Arch Dis Child 1978;53:262.
104. Mathur NB, Subramanian BK, Sharma VK, Puri RK. Exchange transfusion in neutropenic septicemic neonates: effect on granulocyte functions. Acta Paediatr 1993;82:939-43.
105. Cairo MS, Worcester CC, Rucker RW, et al. Randomized trial of granulocyte transfusions versus intravenous immune globulin therapy on neonatal neutropenia and sepsis. J Pediatr 1992;120:281-5.
106. Baird JS, Johnson J. Management of neonatal sepsis (letter). J Pediatr 1992;121:497-8.
107. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet 1991;337:867-72.
108. Chalmers TC, Block JB, Lee S. Controlled studies in clinical cancer research. N Engl J Med 1972;287:75-8.
109. Sacks HS, Chalmers TC, Smith H Jr. Sensitivity and specificity of clinical trials: randomized v historical controls. Arch Intern Med 1983;143:753-5.
110. Colditz GA, Miller JN, Mosteller F. How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med 1989;8:441-54.
111. Miller JN, Colditz GA, Mosteller F. How study design affects outcomes in comparisons of therapy. II: Surgical. Stat Med 1989;8:455-66.
112. Gerbarg ZB, Horwitz RI. Resolving conflicting clinical trials: guidelines for meta-analysis. J Clin Epidemiol 1988;41:503-9.
113. Detsky AS, Naylor CD, O'Rourke K, et al. Incorporating variations in the quality of individual randomized trials into metaanalysis. J Clin Epidemiol 1992;45:255-65.
114. Zelen M. Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors. J Clin Oncol 1983;1:164-9.
115. Lichtenstein MJ, Mulrow CD, Elwood PC. Guidelines for reading case-control studies. J Chronic Dis 1987;40:893-903.
116. Feinstein AR. Clinical epidemiology: the architecture of clinical research. Philadelphia: WB Saunders, 1985:543-7.
117. Heddle NM, Blajchman MA. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions. Blood 1995;85:603-6.
118. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990;6:5-30.
119. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
120. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 1990;142:612-28.
121. Klein S, Simes J, Blackburn GL. Total parenteral nutrition and cancer clinical trials. Cancer 1986;58:1378-86.
122. Slavin RE. Best-evidence synthesis: an alternative approach to traditional and meta-analytic reviews. Educ Res 1986;15:5-11.
123. Slavin RE. Best-evidence synthesis: why less is more. Educ Res 1987;16:15-6.
124. Liberati A, Himel HN, Chalmers TC. A quality assessment of randomized controlled trials of primary treatment of breast cancer. J Clin Oncol 1986;4:942-51.
125. Vamvakas EC, Moore SB. Blood transfusion and postoperative septic complications. Transfusion 1994;34:714-27.
126. Eysenck HJ. An exercise in megasilliness. Am Psychol 1978;35:517.
127. Wachter KW. Disturbed by meta-analysis? Science 1988;241:1407-8.
128. Huque MF. Experiences with meta-analysis in FDA submissions. Proc Biopharmaceut Sect Am Stat Assoc 1988;2:28-33.
129. Dubey S. Regulatory considerations on meta-analysis and multicenter trials. Proc Biopharmaceut Sect Am Stat Assoc 1988;2;18-27.
130. Stein RA. Meta-analysis from one FDA reviewer's perspective. Proc Biopharmaceut Sect Am Stat Assoc 1988:2;34-8.
131. Chalmers TC. Problems induced by meta-analyses. Stat Med 1991;10:971-9; discussion, 979-80.
132. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987;9:1-30.
133. Abramson JH. Meta-analysis: a review of pros and cons. Public Health Rev 1990-91;18:1-47.
134. Greenland S, Longnecker MP. Methods for trend estimation from summarized dose-response data, with applications to meta-analysis. Am J Epidemiol 1992;135:1301-9.
135. Greenland S, Salvan A. Bias in the one-step method for pooling study results. Stat Med 1990;9:247-52.
136. Cook TD, Cooper H, Cordray DS, et al. Meta-analysis for explanation: a casebook. New York: Russell Sage Foundation, 1992.
137. Ellenberg SS. Meta-analysis: the quantitative approach to research review. Semin Oncol 1988;15:472-81.
138. Davis W, Breslow NE, Day NE. Statistical methods in cancer research, vol 1. The analysis of case-control studies. Lyon, France: International Agency for Research on Cancer, 1980.
139. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. Belmont, CA: Lifetime Learning Publications, 1982.
140. Hewitt P, Chalmers TC. Using MEDLINE to peruse the literature. Controlled Clin Trials 1985;6:75-83.
141. Hewitt P, Chalmers TC. Perusing the literature. Methods of accessing MEDLINE and related databases. Controlled Clin Trials 1985;6:168-77.
142. Poynard T, Conn HO. The retrieval or randomized clinical trials in liver disease from the medical literature. A comparison of MEDLARS and manual methods. Controlled Clin Trials 1985;6:271-9.
143. Dickersin K, Kewitt P, Mutch L, et al. Perusing the literature: comparison of MEDLINE searching with a perinatal trials data-base. Controlled Clin Trials 1985;6:306-17.
144. Haynes RB, McKibbon KA, Walker CJ, et al. Computer searching of the medical literature. An evaluation of MEDLINE searching systems. Ann Intern Med 1985;103:812-6.
145. Begg CB, Berlin JA. Publication bias and dissemination of clinical research. J Natl Cancer Inst 1989;81:107-15.
146. Begg CB, Berlin JA. Publication bias: a problem in interpreting medical data. J R Stat Soc A 1988;151:419-63.
147. Simon R. Randomized clinical trials and research strategy. Cancer Treat Rep 1982;66:1083-7.
148. Zelen M. Strategy and alternate randomized designs in cancer clinical trials. Cancer Treat Rep 1982;66:1095-100.
149. Fleming TR. Historical controls, data banks, and randomized trials in clinical research: a review. Cancer Treat Rep 1982;66:1101-5.
150. Dickersin K, Chan S, Chalmers TC, et al. Publication bias and clinical trials. Controlled Clin Trials 1987;8:343-53.
151. Simes RJ. Confronting publication bias: a cohort design for meta-analysis. Stat Med 1987;6:11-29.
152. Pocock SJ, Hughes MD. Estimation issues in clinical trials and overviews. Stat Med 1990;9:657-71.
153. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol 1986;4:1529-41.
154. Koren G, Graham K, Shear H, Einarson T. Bias against the null hypothesis: the reproductive hazards of cocaine. Lancet 1989;2:1440-2.
155. Dickersin K, Min YI, Meinert CL. Factors influencing publication of research results. Follow-up of applications submitted to two institutional review boards. JAMA 1992;267:374-8.
156. Chalmers I, Adams M, Dickersin K, et al. A cohort study of summary reports of controlled trials. JAMA 1990;263:1401-5.
157. Detsky AS, Baker JP, O'Rourke K, Goel V. Perioperative parenteral nutrition: a meta-analysis. Ann Intern Med 1987;107:195-203.
158. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA 1990;263:1385-9.
159. Chalmers I. Underreporting research is scientific misconduct. JAMA 1990;263:1405-8.
160. Davidson RA. Source of funding and outcome of clinical trials. J Gen Intern Med 1986;1:155-8.
161. Lauritsen K, Havelund T, Laursen LS, Rask-Madsen J. Withholding unfavourable results in drug company sponsored clinical trials (letter). Lancet 1987;1:1091.
162. Kochar MS. The peer review of manuscripts - in need for improvement. J Chronic Dis 1986;39:147-9.
163. A proposal for more informative abstracts of clinical articles. Ad Hoc Working Group for Critical Appraisal of the Medical Literature. Ann Intern Med 1987;106:598-604.
164. Easterbrook P. Reducing publication bias (letter). Br Med J (Clin Res Ed) 1987;295:1347.
165. Hetherington J, Dickersin K, Chalmers I, Meinert CL. Retrospective and prospective identification of unpublished controlled trials: lessons from a survey of obstetricians and pediatricians. Pediatrics 1989;84:374-80.
166. Stock WA, Okun MA, Haring MJ, et al. Rigor in data synthesis: a case study of reliability in meta-analysis. Educ Res 1982;11:10-14, 20.
167. Smith ML, Glass GV. Meta-analysis of psychotherapy outcome studies. Am Psychol 1977;32:752-60.
168. Littenberg B. Aminophylline treatment in severe, acute asthma. A meta-analysis. JAMA 1988;259:1678-84.
169. Chalmers TC, Berrier J, Sacks HS, et al. Meta-analysis of clinical trials as a scientific discipline. II: Replicate variability and comparison of studies that agree and disagree. Stat Med 1987;6:733-44.
170. Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet 1995;345:772-6.
171. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Examples from the management of acute myocardial infarction. Ann Intern Med 1995;123:873-7.
172. Naylor CD. Two cheers for meta-analysis: problems and opportunities in aggregating results of clinical trials. Can Med Assoc J 1988;138:891-5.
173. Discussion of Peto R. Why do we need systematic overviews of randomized trials? In: Yusuf S, Simon R, Ellenberg S, eds. Proceedings of conference on methodologic issues in overviews of randomized clinical trials. Stat Med 1987;6:241-4.
174. Jadad AR, McQuay HJ. Meta-analyscs to evaluate analgesic interventions: a systematic qualitative review of their methodology. J Clin Epidemiol 1996;49:235-43.
175. Wittes RE. Problems in the medical interpretation of overviews. Stat Med 1987;6:269-80.
176. Thompson SG. Why sources of heterogeneity in meta-analysis should be investigated. BMJ 1994;309:1351-5.
177. Blumberg N, Heal JM. Effects of transfusion on immune function. Cancer recurrence and infection. Arch Pathol Lab Med 1994;118:371-9.
178. Marquet RL, Hoynck van Papendrecht MA, Busch OR, Jeekel J. Blood donation leads to a decrease in natural killer cell activity: a study in normal blood donors and cancer patients. Transfusion 1993;33:368-73.
179. Heiss MM, Mempel W, Jauch KW, Schildberg FW. Leukocytedepleted or buffy coat-depleted blood in surgery for colorectal cancer (letter). Lancet 1994;344:1429-30; discussion, 1430-1.
180. Waymack JP, Robb E, Alexander JW. Effect of transfusion on immune function in a traumatized animal model. II. Effect on mortality rate following septic challenge. Arch Surg 1987;122:935-9.
181. Waymack JP, Chance WT. Effect of blood transfusions on immune function: IV. Effect on tumor growth. J Surg Oncol 1988;39:159-64.
182. Persijn GG, Cohen B, Lansbergen Q, van Rood JJ. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 1979;28:396-401.
183. Hennekens CH, Buring JE, Hebert PR. Implications of overviews of randomized trials. Stat Med 1987;6:397-409.
184. Ridker PM, Buring JE, Hennekens CH. Meta-analysis in cardiovascular disease: strengths and limitations. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, vol 3. 4th ed. Philadelphia: Saunders, 1992:54-64.